Press Room

Hovione speakers at the QRM Summit

Start
Thursday, May 11, 2017 - 08:30
End
Thursday, May 11, 2017 - 15:30
Location: Lisbon, Portugal

HOVIONE PRESENTATIONS

Guy Villax, CEO
8:30 - 9:15 am

Guy Villax will be the keynote speaker at the second day of the Quality Risk Management Summit. Under the Supply Chain Integrity block, Guy's talk will address the topic Do patients want capsules full of compliance, or full of quality? Why Quality culture wins every time.

 

Joerg Gampfer, Senior Director Quality
11:30 - 12:00

The whole is more than the sum of the pieces - building strategy on Knowledge and Risk Management

 

Luisa Paulo, GMP Compliance Director and ICH Q12 Team Member
14:00 - 15:00

QRM Enabled Post-Approval Changes & Lifecycle Management within ICHQ12

 

You might be also interested in:

 

Quality Culture Wins Over Compliance

Pharma's Almanac, June 2016

Why Dr. Hamburg Needs Her Dean’s List

Guy Villax Letter, June 2014

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026